Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Vusolimogene oderparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 08 Mar 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 29 Feb 2024 Status changed from not yet recruiting to recruiting.